Power 3 Medical Products Inc. (PWRM) is a development-stage biotechnology company specializing in the early detection of breast cancer, Alzheimer's disease, Lou Gehrig's disease, Parkinson's disease, leukemia, gastrointestinal disease and metabolic syndrome. The Company focuses upon the study of proteomics, which identifies 334 protein biomarkers for the above-named diseases.
In the report, the analyst notes:
"The Company presently operates at a deficit, with minimal operating revenues from the sale of its products and services at this time. Management is pursuing third-party licensing, collaboration and distribution agreements to generate revenue from its disease diagnosis biomarker and drug resistance identification systems. The Company's proprietary identification system aids in the areas of various cancers, neurodegenerative and neuromuscular diseases.
"The Company's goal is to complete phase II of its testing to identify Alzheimer's and Parkinson's disease. Partnering with Transgenomic Inc., the Company expects to complete phase II and begin to commercialize its testing products during the first quarter of 2010.
"The Company stated in its latest 10-Q of November 16, that it seeks grants and other sources of funding to take its BC-SeraPro(TM) and NuroPro Blood Test to full commercialization and to continue operations."